Organized by J.P. Morgan, the J.P. Morgan Healthcare Conference is a four-day conference bringing together emerging fast-growth companies, members of the investment community, industry leaders, and innovative technology creators in healthcare. It is the industry’s largest healthcare investment conference.
Between January 7-10, American Gene Technologies’s CEO Jeff Galvin, CFO Neil Lyons, Norman Rogers, Drew Palin, and Morgan Stevens will also attend the following events in San Francisco: Redefining Early Stage Investments (RESI) Conference, Biotech Showcase, and BIO One-on-One Partnering. In all, they will participate in over 100 meetings.
AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including: large and orphan indications, infectious disease, immuno-oncology, and monogenic disorders. AGT expects to take its patented, lead candidate for an HIV Cure into the clinic in 2019. It has pioneered a novel immuno-oncology approach of stimulating gamma-delta (γδ) T cells to attack a variety of cancers. Four key patents in AGT’s novel immuno-oncology approach have been granted. AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine.